[1]许虎军１,阮家安２,高峰３,等.沙藤红曲软胶囊治疗高脂血症的临床研究[J].现代中医药,2019,(05):061-64.[doi:10.13424/j.cnki.mtcm.2019.05.019]
　Xu Hujun Ruan Jia an Gao Feng Li Min.Clinical Study on Treatment of Hyperlipidemia with Shateng Hongqu Soft Capsule[J].Modern Traditional Chinese Medicine,2019,(05):061-64.[doi:10.13424/j.cnki.mtcm.2019.05.019]
点击复制

沙藤红曲软胶囊治疗高脂血症的临床研究()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2019年05期
页码:
061-64
栏目:
临床研究
出版日期:
2019-09-16

文章信息/Info

Title:
Clinical Study on Treatment of Hyperlipidemia with Shateng Hongqu Soft Capsule
文章编号:
1672-0571(2019)05-0061-04
作者:
许虎军１; 阮家安２; 高峰３; 李敏３
渭南职业技术学院
Author(s):
Xu Hujun 1 Ruan Jia’ an 2 Gao Feng 3 Li Min 3
1. Weinan Vocational and Technical College, Weinan China, 714026; 2. Baihe People’ s Hospital, Baihe China, 725800; 3. Shaanxi University of Chinese Medicine, Xiangyang China 712046
关键词:
沙藤红曲软胶囊; 高脂血症; 炎性因子; 动脉粥样硬化
Keywords:
Shateng Hongqu Soft Capsule;  hyperlipidemia;  inflammatory factor;  atherosclerosis
分类号:
R543
DOI:
10.13424/j.cnki.mtcm.2019.05.019
文献标志码:
A
摘要:
研究沙藤红曲软胶囊治疗高脂血症以及对炎性因子 ＴＮＦ－ɑ、ＩＬ－６的影响。方法 采用双盲、 随机、平行对照等原则进行实验设计，治疗组给予受试药物沙藤红曲软胶囊，对照组则给予安慰剂，疗程 ９０天。 试验进入统计分析的有效例数为治疗组 ５８例，对照组 ５６例。试验结束揭盲后，分析沙藤红曲软胶囊治疗高脂 血症患者炎性因子 ＴＮＦ－ɑ和 ＩＬ－６的影响。结果 治疗组患者的总胆固醇（ＴＣ）有效率为 ６５．５２％、甘油三酯 （ＴＧ）的有效率为 ５１．７２％、高密度脂蛋白（ＨＤＬ－Ｃ）的有效率为 ４４．８３％，其分别明显高于安慰剂对照组的 ７．１４％、８．９３％和 ２８．５７％。经对比分析得出，治疗组的 ＴＣ、ＴＧ值显著低于对照组，ＨＤＬ－Ｃ值显著高于对照 组；炎性因子 ＴＮＦ－ɑ、ＩＬ－６均低于对照组，且具有统计学意义。结论 沙藤红曲软胶囊不仅可以有效地调节高 脂血症患者的血脂水平，还可以通过降低 ＴＮＦ－ɑ、ＩＬ－６以抑制血管动脉粥样硬化
Abstract:
To study the effect of Shateng Hongqu Soft Capsule on hyperlipidemia and inflammatory factors TNF - a and IL -6. Methods: The experimental design was based on the principles of double blindness, randomization and parallel control. The treatment group was given Shateng Hongqu Soft Capsules, while the control group was given placebo for 90 days. The effective cases of the experiment were 58 cases in the treatment group and 56 cases in the control group. After the blindness was uncovered, the effects of Shateng Hongqu Soft Capsule on inflammatory factors TNF – a and IL -6 in patients with hyperlipidemia were analyzed. Results: TThe total cholesterol ( TC) effective rate was 65.52%, the triglyceride ( TG) efficiency was 51. 72%, and the high density lipoprotein ( HDL - C) was 44. 83%, which were significantly higher than those of the placebo control group ( 7. 14%, 8. 93% and 28. 57%) . Through comparative analysis, TC and TG values in the treatment group were significantly lower than those in the control group, HDL - C values were significantly higher than those in the control group, and inflammatory factors TNF - a and IL - 6 were lower than those in the control group, with statistical significance. Conclusion: Shateng Hongqu Soft Capsule can not only effectively regulate the blood lipid level of patients with hyperlipidemia, but also inhibit vascular atherosclerosis by reducing TNF - a and IL -6.

参考文献/References:

[1]米良荣.2007-2009年我院口服降血脂药物应用分析[J].中国医药导刊,2011,13(2):307-308.
[2]赵丹丹.载脂蛋白A5?C3和E基因多态性与高脂血症痰瘀互阻证及其疗效的关系[D].北京:中国中医科学院,2007. [ 3] The medical letter, Inc. Choice of lipid— regulating drugs [ J] . Medlettdrug Ther,2001,43( 1105) :43.
[4]张振强.内科学[M].西安:第四军医大学出版社,2013:195-199.
[5]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:254-257.
[6]李剑红,王丽敏.2010年我国成年人血脂异常流行特点[J].中华预防医学杂志,2012,46(5):414-418.
[7]血脂治疗现状调查协作组.我国高脂血症治疗现状的调查[J].中华心血管病杂志,2001,29(1):15~17.
[8]张文文,王秀梅.血脂水平对sPESI评分为高危的急性肺动脉栓塞患者的预测作用[J].中国实用医药,2016,11(29):10-12. [ 9] American Gastroenterological Association. A – merican Gastroenterological AssociationMedi - cal Position Statement: nonalcoholic fatty liverdisease. Gastroenterology,2002,123:1702 -1704.
[10]刘朝降.2型糖原病非增殖性视网膜病变血脂异常与膜岛素抵抗的关系[J].中国医疗前沿,2011,17(6):26-27. [ 11] Amstrong VM. The association between LP( a) eoneentrations and angiographically assessed coronary atheroselerosis [ J] . Atheroselerosis,1989,62( 4) :249. [ 12] Napolip D, Taccardi AA, Oliver M, et al. Statins and stroke: Evidence forCholesterol - Independent Effects [ J] . Eur Heart J,2002,23( 24) :1908 -1921. [ 13] Popa C, Netea M G, van Riel P L, et al. The role of TNF - alpha in chronic inflamematory conditions, intermediary metabolism, and cardiovascular risk [ J] . J Lipid Res. 2007,48( 4) : 751 -762. [ 14] Cruickshank AM, Oldroyd KG, Cobbs. et al. Serum IL- 6 in suspected myocardial infarction [ J] . Lancet.1994; 343( 8903 ) ;974. [ 15] Al Ian Ml, Rosario S, David J. Vaseular effects of HMG- Co A reductase inhibitors( statins) unrelated cholesterol lowering: new concepts for cardiovascular disease. Cardiovase Res, 2001, 49 ( 2) : 281 -287.

相似文献/References:

[1]张健俊１ 刘文洲２ 欧莉３.红杏丸治疗高脂血症临床研究 及其对 ＴＮＦ－ɑ、ＩＬ－６、ＥＴ－１的影响[J].现代中医药,2019,(02):096.[doi:10.13424/j.cnki.mtcm.2019.02.029]
　Zhang Jianjun Liu Wenzhou Ou Li.Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF - ɑ, IL -6 and ET -1[J].Modern Traditional Chinese Medicine,2019,(05):096.[doi:10.13424/j.cnki.mtcm.2019.02.029]
[2]何 平.五脏论治高脂血症的理论及经验总结[J].现代中医药,2020,(01):027.[doi:10.13424/j.cnki.mtcm.2020.01.007]
[3]刘睿位佳琳位鸿 尚坤 何蕊 陈少波 汪景 杨戈.泽明降脂颗粒制备工艺的优化及 质量标准研究[J].现代中医药,2022,1(05):033.[doi:10.13424/j.cnki.mtcm.2022.05.006]
[4]杨洋刘昳张哲郑清莲刘艳张莹李帅.郑清莲教授应用三仁汤加减治疗高脂血症经验[J].现代中医药,2024,(01):020.[doi:10.13424/j.cnki.mtcm.2024.01.005]
　YANG YangLIU YiZHANG ZheZHENG QinglianLIU YanZHANG YingLI Shuai.Professor ZHENG Qinglians Experience in TreatingHyperlipidemia with Modified SanrenDecoction for Tongli Sanjiao[J].Modern Traditional Chinese Medicine,2024,(05):020.[doi:10.13424/j.cnki.mtcm.2024.01.005]

备注/Memo

备注/Memo:
基金项目：陕西秦岭中草药应用开发工程技术研究中心（２００８ＺＤＧＣ－３２）
更新日期/Last Update: 2019-09-15